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Abstract
Background: The population of elderly end-stage renal dis-
ease patients initiating dialysis is rapidly growing. Although 
longer treatment is supposed to benefit for hemodialysis 
(HD) patients through more solute clearance and slower flu-
id removal, it is not yet clear how treatment session length 
affects mortality risk in octogenarians and nonagenarians. 
Methods: In a cohort of 112,026 incident HD patients be-
tween 2007 and 2011, we examined the association of treat-
ment session length with all-cause mortality, adjusting for 
demographics and comorbid conditions. We also used re-
stricted spline functions for age to evaluate continuous 
changes in the association of short (< 210 min) and extended 
(≥240 min) HD treatment (vs. 210 to < 240 min) with all-cause 
mortality over continuous age. Results: During the first 91 
days of dialysis, patients aged ≥80 years tended to have the 
lowest treatment session length (median [interquartile 
range] 211 [193–230] min, r > 0.5). Longer treatment was as-
sociated with better survival in patients < 65 and 65 to < 80 
years but not in octogenarians/nonagenarians. The associa-
tion of extended treatment (≥240 min) with better survival 
was attenuated across age and not significant among pa-
tients aged ≥80 years with a hazard ratio of 1.10 (95% CI 
0.99–1.20). Shorter treatment sessions (< 210 min) was asso-
ciated with higher mortality across all age groups. Conclu-
sion: Extended HD was not associated with lower mortality 
among octogenarians and nonagenarians, while it was as-
sociated with better survival among younger patients. Fur-
ther studies are needed to determine the optimal treatment 
session length in elderly incident HD patients.
© 2018 S. Karger AG, Basel
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Introduction
Despite medical advances and improvements in pa-
tient care, the mortality of end-stage renal disease (ESRD) 
patients on dialysis treatment remains unacceptably high 
[1]. Although there have been many studies for optimiz-
ing treatment session length in hemodialysis (HD) pa-
tients as an effort to improve survival by delivering the 
ideal dose of dialysis and reducing complications [2–7], 
it has not been clear yet which treatment session length is 
necessary for achieving better clinical outcomes. 
Elderly patients are the fastest growing dialysis popu-
lation according to the United States Renal Data System 
[1, 8]. There are several factors that may warrant the need 
to modify the risk-benefit balance of extended dialysis 
particularly in this population [9–11]: (1) smaller increas-
es in uremic burden or volumes due to lower dietary in-
take, compared with those in younger patients; (2) higher 
risk of HD-related complications; and (3) compromised 
quality of life by longer dialysis sessions.
Therefore, we examined whether there is a differential 
association between HD treatment session length and all-
cause mortality risk across age groups in a contemporary 
cohort of incident HD patients. 
Materials and Methods
The study was approved by the Institutional Review Boards of 
the Los Angeles Biomedical Research Institute at Harbor-UCLA 
and the University of California Irvine Medical Center.
Study Population
We conducted a historical cohort study of incident HD patients 
receiving dialysis care from a large dialysis organization (LDO) in 
the United States, with comprehensive longitudinal data on pa-
tients’ sociodemographics, comorbidities, laboratory tests, dialysis 
treatment characteristics, clinical events, and vital status. The orig-
inal source population was a cohort of 208,820 incident dialysis 
patients receiving care in one of the LDO outpatient facilities over 
a 5-year period (January 2007 to December 2011). Among 133,162 
incident ESRD patients who received dialysis treatment for at least 
60 days and were treated only by in-center thrice-weekly HD dur-
ing the follow-up, we excluded 21,036 patients if they were ≤18 and 
> 100 years old or had missing baseline HD treatment session 
length data. The follow-up time was divided into patient-quarters 
(i.e., 91-day periods from the date of first dialysis), where baseline 
was considered the first 91-day period.
Exposure Ascertainment
Quarterly averaged values of HD treatment session length dur-
ing the first quarter of dialysis treatment were grouped into the 
following categories: < 180 min, 180 to < 210 min, 210 to < 240 min, 
and ≥240 min. Patients were also categorized according to their 
age at study entry: < 65, 65 to < 80, and ≥80 years. 
Outcome Assessment
The primary outcome of interest was all-cause mortality. Pa-
tients were censored for death, kidney transplantation, transfer to 
a non-LDO dialysis unit, recovery of renal function or dialysis dis-
continuation, or at the end of the study (December 31, 2011). In 
the primary analyses, we sought to compare the association of 
treatment session length with all-cause mortality risk across age 
groups.
Sociodemographic, Dialysis Treatment, and Laboratory 
Characteristics
Information regarding sociodemographics (including self-re-
ported race/ethnicity and primary insurance type) as well as co-
morbid conditions (e.g., diabetes mellitus, hypertension, athero-
sclerotic heart disease, congestive heart failure, other cardiac dis-
eases, cerebrovascular disease, chronic obstructive pulmonary 
disease, and history of cancer or liver disease) defined by the Inter-
national Classification of Diseases-9 codes was also obtained from 
the LDO database. The modified Deyo-Charlson comorbidity in-
dex, where we excluded the presence or absence of kidney disease, 
was also obtained from the LDO database [12, 13]. 
Blood samples for laboratory tests were collected before dialy-
sis, except for post-dialysis serum urea nitrogen, using standard-
ized techniques in all dialysis clinics. These samples were trans-
ported to a central laboratory in Deland, Florida, normally within 
24 h, where they were measured using automated and standard-
ized methods. Most laboratory tests were performed monthly, in-
cluding serum creatinine, albumin, peripheral white blood cell 
count, total iron binding capacity, calcium, phosphorus, and bicar-
bonate. Serum intact parathyroid hormone was usually measured 
at least once per quarter. Hemoglobin was measured weekly to 
biweekly in most patients. The delivered dialysis dose was calcu-
lated by single-pool Kt/V using urea kinetic modeling. The nor-
malized protein catabolic rate (nPCR) was calculated. To mini-
mize measurement variability, all repeated measures for each 91-
day interval were averaged, and the quarterly mean values were 
used in analyses. 
Statistical Analysis
Baseline characteristics across age groups and treatment time 
groups are summarized as proportions, mean ± SD, or medians 
(interquartile ranges [IQR]) depending on the data type. We used 
logistic regression to estimate the association between various clin-
ical characteristics and the likelihood of extended treatment ses-
sion length (treatment session length ≥240 vs. 180 to < 240 min) 
within age groups. We stratified each age group according to the 
treatment session length, and using Cox proportional hazard mod-
els, we compared the association of treatment session length with 
all-cause mortality risk across age groups using 3 hierarchical lev-
els of adjustment:
(1) Unadjusted model: Included the main predictor, treatment 
session length
(2) Case-mix adjusted model: Included the unadjusted model 
covariates as well as age, sex, race/ethnicity, primary insurance 
type, 10 comorbid conditions (diabetes mellitus, hypertension, 
atherosclerotic heart disease, congestive heart failure, other car-
diovascular disease, cerebrovascular disease, dyslipidemia, chron-
ic obstructive pulmonary disease, liver disease, and history of ma-
lignancy), dialysis dose as measured by single-pool Kt/V, body 
mass index (BMI), and ultrafiltration rate (mL/h/kg body weight)
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(3) Case-mix + malnutrition-inflammation-cachexia syn-
drome model: Included the case-mix adjusted model covariates as 
well as 10 clinically relevant laboratory variables (white blood cell 
count, hemoglobin, serum albumin, creatinine, bicarbonate, un-
corrected calcium, phosphorus, intact parathyroid hormone, total 
iron binding capacity, and nPCR)
We defined the case-mix model as our preferred model, which 
included core sociodemographic measures and other confounders 
of the association between treatment session length and outcomes. 
The malnutrition-inflammation-cachexia syndrome model was 
designated an exploratory model, which included confounders as 
well as potential intermediates on the causal pathway of treatment 
session length and mortality association. We also conducted sub-
group analyses in which we compared the association of short 
(<  210 min) or extended treatment (≥240 min) vs. conventional 
treatment (210 to < 240 min) with mortality across age groups.
Effect modifications of the association between treatment ses-
sion length (short: < 210 min or extended treatment: ≥240 min vs. 
the standard treatment (210–240 min) and all-cause death by age 
were examined with restricted cubic spline functions for age in the 
case-mix adjusted model. The frequency of missing data was low 
(1%) for most laboratory tests, except for nPCR (4%) and creati-
nine (4%), and the multiple imputation method with 5 datasets was 
used in all regression analyses. All analyses and figures were gener-
ated with STATA MP, version 13.1 (StataCorp, College Station, 
TX, USA) and SigmaPlot version 12.5 (Systat Software, San Jose, 
CA, USA).
Results
Study Population Description
The study population included 112,026 incident HD 
patients (online suppl. Fig. 1; for all online suppl. mate-
rial, see www.karger.com/doi/10.1159/000494336). The 
mean ± SD age of the overall cohort was 63 ± 15 years, 
and the median treatment session length (IQR) was 211 
(193–230) min. The crude all-cause mortality rate of the 
overall cohort was 135 death events per 1,000 patient-
years of follow-up (95% CI 133–136). Across all age 
groups, the baseline treatment session length distribution 
showed 3 distinct curves peaking at approximately 180, 
210, and 240 min. Patients aged ≥80 years tended to have 
the lowest baseline treatment session length (median 
[IQR] 204 [184–217] min), with the highest peak at ap-
proximately 180 min, whereas patients aged < 65 years 
had the greatest treatment session length (median [IQR] 
214 [199–234] min), with the highest peak at approxi-
mately 240 min (Fig. 1). Baseline characteristics of the co-
hort stratified by age and baseline treatment session 
length are presented in Table 1. Across all age groups, 
patients with the highest treatment session length tended 
to be male; were more likely to be African American and 
less likely to be Hispanic or Asian; were more likely to use 
a central venous catheter as their primary vascular access; 
were more likely to have diabetes, atherosclerotic heart 
disease, and other cardiovascular diseases; and had high-
er BMI compared to those in the lowest treatment session 
length category. Ultrafiltration rate tended to be lower in 
the extended treatment time group in all age groups. 
However, intradialytic hypotension was more frequent in 
the extended treatment time group only in patients aged 
≥80 years.
Clinical Characteristics Associated with Extended 
Treatment Time Across Age Groups
Table 2 shows the association between clinical charac-
teristics and the likelihood of extended treatment time 
(treatment session length ≥240 min) across age groups in 
the case-mix adjusted logistic regression models (refer-
ence: treatment session length ≥180 to < 240 min). Across 
all age groups, being female, Hispanic, or Asian; using 
Medicaid insurance; and having an arteriovenous fistula 
(AVF)/ arteriovenous graft (AVG) access type were as-
sociated with a lower likelihood of extended treatment 
time. Being African American, having a diagnosis of dia-
betes or other cardiac disease, and having higher baseline 
BMI and creatinine values were associated with a higher 
likelihood of extended treatment time. 
Treatment Session Length and All-Cause Mortality 
Across Age Groups
In the case-mix adjusted Cox regression analysis, 
there  was a linear inverse association in mortality risk 
with greater treatment session length in patients aged 
0
0.01
0.02
0.03
150 180 210 240 270 300
Treatment session length, min
De
ns
ity
Age <65 years
65≤ age <80 years
Age ≥80 years
Fig. 1. Distribution of baseline hemodialysis (HD) treatment ses-
sion length across age groups with age < 65, 65 to < 80, and ≤80 
years in 112,026 incident HD patients. 
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<  65  years, where extended treatment time (≥240 min) 
was associated with a lower mortality risk (HR [95% CI] 
0.91 [0.86–0.97]). Patients aged 65 to < 80 and ≥80 years 
also had a linear inverse association mortality risk as 
treatment session length increased until < 240 min (refer-
ence: 210-> 240 min). However, unlike patients aged < 65, 
the treatment session length ≥240 min was not associated 
with a lower risk of mortality among patients aged 65 to 
< 80 and ≥80 years (HRs [95% CI] 0.95 [0.90–1.01] and 
1.10 [0.99–1.20] respectively; Fig. 2, online suppl. Fig. 2).
Treatment Session Length and Mortality Across 
Subgroups
Figure 3a and b shows the case-mix adjusted associa-
tions between short (< 210 min) and extended (≥240 min) 
treatment session lengths and all-cause mortality (refer-
ence: ≥210 to < 240 min) across a priori selected sub-
groups and stratified by age. Compared to the association 
of mortality with short treatment session length that did 
not show much difference between age groups (Fig. 3a), 
there was an incremental change in the association of ex-
tended treatment session length with mortality between 
age groups (Fig.  3b). Extended treatment (≥240 min) 
compared to standard treatment (≥210 to < 240 min) 
tended to be associated with a lower risk of mortality in 
those aged < 65 years especially in male, African Ameri-
can, non-diabetes, without congestive heart failure, low 
BMI (≤25), high interdialytic weight gain (IDWG, >3% of 
body weight), high spKt/V (> 1.5), and low albumin (≤3.5 
mg/dL). Extended treatment time was not associated with 
a lower risk of mortality in any subgroups of patients aged 
65 to < 80 and ≥80 years. In the subgroup of white patients 
aged ≥80 years, extended treatment (≥240 min) was as-
sociated with a higher risk of mortality.
Table 2. Association of clinical characteristics with extended hemodialysis treatment time (treatment session length ≥240 vs. ≥180 to 
<240 min) among the three age groups (<65, 65 to <80, and ≥80 years) in case-mix adjusted logistic regression models
Factor Age, years
<65
OR (95% CI)
65 to <80
OR (95% CI)
≥80
OR (95% CI)
Socio-demographic factors
Age, per 5 years 1.00 (1.00–1.00) 0.99 (0.98–1.00) 0.94 (0.93–0.97)
Female (vs. male) 0.48 (0.45–0.51) 0.43 (0.40–0.47) 0.33 (0.28–0.39)
Race: African American (vs. white) 1.17 (1.11–1.25) 1.20 (1.10–1.30) 1.26 (1.05–1.51)
Race: Asian (vs. white) 0.76 (0.70–0.82) 0.62 (0.54–0.70) 0.67 (0.51–0.89)
Race: hispanic (vs. white) 0.64 (0.52–0.80) 0.33 (0.24–0.46) 0.32 (0.17–0.62)
Insurance: medicaid (vs. medicare) 0.69 (0.63–0.75) 0.64 (0.48–0.85) 0.61 (0.30–1.22)
Insurance: other insurance (vs. medicare) 0.91 (0.86–0.96) 0.94 (0.87–1.01) 1.09 (0.93–1.26)
Comorbidity factors
Diabetes 1.18 (1.11–1.25) 1.12 (1.04–1.21) 1.21 (1.05–1.39)
Hypertension 1.13 (1.07–1.19) 1.06 (0.98–1.14) 1.05 (0.91–1.21)
Congestive heart failure 0.93 (0.88–0.98) 0.91 (0.84–0.98) 1.00 (0.87–1.16)
Atherosclerotic heart disease 1.02 (0.94–1.10) 0.98 (0.88–1.08) 0.96 (0.80–1.15)
Other cardiac diseases 1.10 (1.01–1.20) 1.21 (1.09–1.34) 1.30 (1.09–1.56)
Dialysis related factors
Access type: AVF (vs. CVC) 0.64 (0.59–0.69) 0.65 (0.58–0.72) 0.62 (0.50–0.77)
Access type: AVG (vs. CVC) 0.55 (0.47–0.65) 0.51 (0.42–0.62) 0.59 (0.41–0.85)
BMI, per 1 kg/m2 1.06 (1.05–1.06) 1.06 (1.05–1.07) 1.06 (1.05–1.07)
Ultrafiltration, per 1 kg 1.49 (1.45–1.54) 1.50 (1.44–1.57) 1.45 (1.31–1.59)
Pre–HD SBP, per 10 mm Hg 1.00 (0.99–1.00) 1.00 (0.99–1.00) 1.00 (0.99–1.00)
Laboratory variables  
Hemoglobin, per 1 g/dL 1.13 (1.11–1.16) 1.14 (1.10–1.17) 1.17 (1.10–1.24)
White blood cell counts, per 103/µL 0.98 (0.97–0.99) 0.99 (0.98–1.01) 0.99 (0.96–1.01)
Albumin, per 1 g/dL 1.00 (0.95–1.06) 0.92 (0.84–0.99) 0.84 (0.72–0.99)
Creatinine, per 1 mg/dL 1.06 (1.05–1.07) 1.09 (1.07–1.12) 1.09 (1.05–1.14)
AVF, arteriovenous fistula; AVG, arteriovenous graft; CVC, central venous catheter; BMI, body mass index; HD, hemodialysis; SBP, 
systolic blood pressure.
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Effect Modification by Age on the Association of 
Treatment Session Length with All-Cause Mortality
We then examined the effect modification by age on 
the association of treatment session length with all-
cause mortality in a continuous pattern using a restrict-
ed cubic spline function in the case-mix adjusted model. 
Using patients with standard treatment (≥210 to < 
240  min) as reference, treatment session length < 210 
min was associated with a higher risk of mortality across 
all ages, though the effect was attenuated along with in-
crease of age (Fig. 4a). Conversely, the HR of all-cause 
mortality in association with extended treatment ses-
sion length (≥240 min) was modified by age; lower risk 
of mortality with extended treatment session length in 
younger patients was incrementally attenuated across 
age (Fig. 4b). In a sensitivity analysis using different cut-
off values for treatment time, age also did not modify the 
association of shorter treatment session length (< 195 
min) with all-cause mortality. However, the association 
of longer treatment time (≥225 min) with all-cause mor-
tality was modified by age in a similar linear pattern, 
where it was associated with a higher risk of mortality in 
those aged 80 years, though it did not reach statistical 
significance (online suppl. Fig. 3).
Discussion
In a nationally representative cohort of incident US 
HD patients, we observed an association of longer 
treatment session length with a lower risk of all-cause 
mortality in patients aged < 65 years, even beyond the 
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Fig. 2. The hazard ratios for all-cause mortality associated with HD 
treatment time across the age groups; (a) < 65 years, (b) 65 to < 80 
years, (c) ≥80 years with hierarchical adjustments (see the Methods 
for detail), and (d) the combination of their case-mix adjustment. 
UFR, ultrafiltration rate; MICS, malnutrition-inflammation- 
cachexia syndrome.
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usual treatment session length of ≥240 min per session. 
However, better survival of patients with extended 
treatment session lengths ≥240 min was not observed 
among patients aged 65 to < 80 and ≥80 years. Risk for 
all-cause mortality in patients with an extended treat-
ment session length (≥240 min) was modified by age, 
whereby a lower risk of mortality was attenuated incre-
mentally across age and tended to be associated with a 
higher risk of mortality in patients aged ≥80 years, al-
though this did not reach statistical significance.
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Fig. 3. Subgroup analysis for the association of short treatment time 
(< 210 min, a) and extended HD treatment time (≥240 min, b) with 
all-cause mortality across age groups. Treatment session length 210 
to < 240 min in each age group was used as a reference group. CHF, 
congestive heart failure; BMI, body mass index; IDWG, interdia-
lytic weight gain; spKt/V, single pool Kt/V; Alb, albumin.
Fig. 4. Change in the association of short HD (treatment session length < 210 min, a) and extend HD treatment 
(≥240 min, b) with all-cause mortality over age with restricted cubic spline functions in the case-mix adjusted 
model.
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Despite the existence of clinical practice guidelines 
and quality improvement programs to achieve optimal 
delivery of dialysis dose, treatment session lengths have 
traditionally been shorter in the United States com-
pared with other international counterparts [14]. Al-
though there was a lack of strong evidence based on ran-
domized clinical trials [15, 16] and earlier studies failed 
to show an association between session length and mor-
tality [17, 18], longer HD treatment sessions have dem-
onstrated benefits in the care [2–4]. Recent publications 
reported that compared to conventional HD (210–240 
min), an extended treatment session of more than 4 h 
was associated with better survival [6, 7, 19, 20]. But, 
there have been variable results regarding the associa-
tion of extended dialysis treatment with mortality [6, 15, 
16, 21].
In the present study, increased treatment session 
length showed a linear association with improved sur-
vival in patients aged < 65 years and 65 to < 80 years, and 
extended treatment session length (≥240 min) was sig-
nificantly associated with better survival in patients aged 
< 65 years. However, longer treatment sessions (≥240 
min) were not associated with better survival in patients 
aged 65 and older and showed a higher risk of mortality 
in the subgroup of white patients aged ≥80 years. Differ-
ent associations of extended treatment session length 
≥240 min with all-cause mortality between patients < 80 
and ≥80 years were shown uniformly in the subgroup 
analysis. The association of better survival resulting 
from extended treatment session lengths ≥240 min was 
attenuated with increased age. The significance of the 
association was lost and extended treatment session 
length was not associated with better survival in patients 
aged ≥80 years. Longer HD treatment sessions are con-
sidered beneficial because they enable the delivery of 
larger doses of dialysis, which enhances solute clearance, 
such as phosphorus and unknown potential mediators 
that cause complications in ESRD [22, 23]. These longer 
sessions also confer better tolerance in the management 
of interdialytic weight gain with preferable ultrafiltra-
tion rates, which has been known to reduce left ventric-
ular hypertrophy and interdialytic hypotension [20, 24, 
25]. However, our findings suggest that the association 
of longer HD treatment with better survival should be 
applied carefully, as longer treatments are not advisable 
for all HD patients. The benefits of extending dialysis 
treatment time in younger patients for the purpose of 
reducing the uremic burden and interdialytic weight 
gain may be diminished in patients aged ≥80 years. 
Moreover, elderly patients were likely more vulnerable 
to the higher risk of intradialytic hypotension probably 
due to higher comorbidities and advanced vascular stiff-
ness when treatment sessions are extended (Table 1). 
The impact of the excerbated loss of nutrient, such as 
from hypercatabolism in extended treatment sessions 
may also be more significant and lead to exceed the ad-
vantage of slower and increasing dose of dialysis in old-
er patients [26].
However, shorter treatment sessions (< 210 min) were 
associated with worse survival regardless of age. Worse 
survival was shown to be associated with shorter treat-
ment (< 210 min) in all subgroups, although some of the 
results were not significant. The adjusted HR ratio analy-
sis also showed worse survival in all age groups. A mini-
mum treatment session length should be recommended 
to ensure the delivery of a proper dose of dialysis and to 
avoid such poor outcomes. Such a recommendation 
would also be helpful to avoid the possibility of an in-
creased ultrafiltration rate due to a shortened dialysis 
time [27, 28]. 
The strengths of our study include its examination of 
a large, nationally representative cohort of dialysis pa-
tients, including more than 15,000 patients aged ≥80 
years; the examination of incident HD patients whose 
characteristics are not confounded by survivor bias; and 
comprehensive availability of detailed, longitudinal pa-
tient-level comorbidity, laboratory, and dialysis treat-
ment data. However, several limitations should be men-
tioned. First, treatment session length data in the first 91 
days were used for the analysis to examine the long-term 
effect of HD treatment time on survival. Though the cor-
relations of treatment session length at baseline with the 
overall study period were good (r > 0.5), baseline value 
may not reflect changes in session length over the course 
of follow-up or the impact of these changes on mortality. 
The overall distribution of treatment session length did 
not vary considerably across the follow-up period as not-
ed in our previous study [29]. There was a good separa-
tion of treatment session length over time between groups 
divided by baseline treatment time, although the differ-
ence in treatment time became smaller, especially during 
the first 6 months (online suppl. Fig. 4). 
Second, cause-specific mortality, which may be helpful 
to better elucidate the underlying mechanisms of the 
treatment session length-mortality association, was not 
examined in this study. 
Third, our study results may be subject to residual 
confounding due to the observational study design and 
inability to adjust for unmeasured potential confound-
ers. Moreover, a greater mortality risk associated with 
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shorter treatment time is at least partly explained by 
indication bias because dying patients are likely to have 
unstable hemodynamics and low dietary intake and, 
hence, are likely to receive prescriptions for shorter 
treatment time in clinical practice. Finally, as with all 
observational studies, our study did not confirm a caus-
al association between patterns of treatment session 
length and mortality. 
In conclusion, extended treatment session length was 
not associated with better survival among octogenarians 
and nonagenarians compared with younger patients. 
However, a shorter treatment session (< 210 min) was as-
sociated with higher mortality risk regardless of age. Fu-
ture studies are needed to determine the underlying 
mechanisms and to further define the optimal, individu-
alized treatment session length management strategies 
for specific patient populations.
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